Phaseline

Companies › Forward Pharmaceuticals

Forward Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FWD1802–Phase 1Healthy; Metastatic Breast CancerMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07476963FWD1802Phase 1HealthyOtherJul 2026
NCT06064812FWD1802Phase 1Metastatic Breast CancerOncologyMar 2028
NCT07002177FWD1802Phase 1Metastatic Breast CancerOncologyMay 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.